Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preemptive Short Course Mavyret in HCV+ to HCV- Kidney Transplantation
NCT04682509Phase 1Completed
- Sponsor
- NYU Langone Health
- Start
- Mar 2022
- Primary completion
- May 2023
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of glecaprevir in hepatitis C (HCV), sponsored by NYU Langone Health. Primary endpoint: Change in the Percentage of Incidence of sustained clearance of HCV (cure) 12 weeks after treatment of viremia. Started Mar 2022; status: completed.
02
Drugs
glecaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT04682509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04682509.